Rotterdam

• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 10 2025-06-25 Sickle cell disease vaso-occlusive crisis
• WOMEN&More: Efficacy, safety, and acceptability of mifepristone 50 mg once-weekly as a contraceptive Ended
  2022-502694-41-00 5 2025-04-14 Contraception
• Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Ended
  2024-511440-76-00 1 2025-03-20 Cutaneous Squamous Cell Carcinoma
• A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) Ended
  2024-515864-30-00 4 2025-03-12 Heterozygous familial hypercholesterolemia
• The rimegePant in RElation to obeSiTy in mIGrainE study Ended
  2024-513359-34-00 6 2025-03-10 Obesity
• A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended
  2024-515959-38-00 4 2025-03-06 Hidradenitis Suppurativa
• A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms Ended
  2024-513258-31-00 3 2024-12-11 Frontotemporal dementia (FTD)
• Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended
  2024-517340-61-00 5 2024-11-19 Patients after curative intent resection of cholangiocarcinoma (intrah
• THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE … Ended
  2024-516260-29-00 5 2024-10-10 non-metastatic (borderline) resectable pancreatic cancer
• Immunogenicity of licensed MF59 adjuvanted Influenza and SARS-CoV-2 vaccine combinations for Older Adults (ISOLDA) Ended
  2024-514798-23-00 4 2024-10-02 COVID-19 and flu
• A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease Ended
  2023-506805-20-01 5 2024-09-25 Neurodegenerative Diseases
• Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF) Ended
  2023-509371-16-00 4 2024-09-25 Idiopathic Pulmonary Fibrosis
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511363-28-00 5 2024-09-24 hidradenitis suppurativa (HS)
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended
  2024-511225-64-00 4 2024-09-18 Alopecia areata
• A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended
  2023-505797-15-00 5 2024-09-13 SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat … Ended
  2023-508170-28-00 4 2024-08-07 alcohol-related liver disease
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age Ended
  2023-503230-49-00 5 2024-07-16 Cystic Fibrosis
• IPAD Trial Ended
  2024-513124-41-00 5 2024-07-12 Primary antibody deficiency: - Unclassified antibody deficiency (unPAD
• Optimizing reversal of HIV latency with combination therapy (pyrimethamine, lenalidomide, panobinostat) Ended
  2024-511192-15-00 4 2024-07-07 HIV-1
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap … Ended
  2022-502653-34-01 11 2024-05-30 Atopic dermatitis and moderate-to severe atopic hand eczema
• A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended
  2023-505022-34-00 4 2024-03-27 Neoplasm malignant

Showing 673–696 of 818 trials